Wakamoto Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wakamoto Pharmaceutical Co., Ltd. with three other
companies in this sector in Japan:
Biofermin Pharmaceutical Company Limited
sales of 11.54 billion Japanese Yen [US$106.43 million]
of which 63%
was New BioferminS),
Koei Chemical Company, Limited
(18.31 billion Japanese Yen [US$168.81 million]
I'rom Group Co Ltd
(10.58 billion Japanese Yen [US$97.53 million]
of which 70%
was Smo Business).
Wakamoto Pharmaceutical Co., Ltd. reported sales of ¥10.74 billion (US$99.02 million)
March of 2019.
decrease of 1.5%
versus 2018, when the company's sales were ¥10.90 billion.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Wakamoto Pharmaceutical Co., Ltd. had sales
of ¥10.32 billion.